Protein / target
Sphingosine 1-phosphate receptor 2
Protein at a glance
Biological role
G protein-coupled peptide receptor activity
Primary system
Nervous system
Strongest disease association
deafness
Therapeutic maturity
Clinically validated target
Druggability
Small molecule
Clinical development
3 approved · 2 in clinical development
Derived from structured UniProt, Open Targets and literature data on this page.
Protein profile
Canonical identity and biological annotation from UniProt.
Function
Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P) (PubMed:10617617, PubMed:25274307). S1P is a bioactive lysophospholipid that elicits diverse physiological effects on most types of cells and tissues (PubMed:10617617). When expressed in rat HTC4 hepatoma cells, is capable of mediating S1P-induced cell proliferation and suppression of apoptosis (PubMed:10617617). Receptor for the chemokine-like protein FAM19A5 (PubMed:29453251). Mediates the inhibitory effect of FAM19A5 on vascular smooth muscle cell proliferation and migration (By similarity). In lymphoid follicles, couples the binding of S1P to the activation of GNA13 and downstream inhibition of AKT activation leading to suppression of germinal center (GC) B cell growth and migration outside the GC niche
Subcellular location
Domains and Gene Ontology detail (18)Hide
Gene Ontology
- Ccytoplasm
- Cglutamatergic synapse
- Cplasma membrane
- Cpresynapse
- FG protein-coupled peptide receptor activity
- FG protein-coupled receptor activity
- FG protein-coupled receptor binding
- Fintegrin binding
- Flipid binding
- Fsphingosine-1-phosphate receptor activity
- Pactin cytoskeleton organization
- Padenylate cyclase-activating G protein-coupled receptor signaling pathway
Biological roles
What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.
View supporting evidenceHide supporting evidence
G protein-coupled signalling
- ·G protein-coupled peptide receptor activity
- ·G protein-coupled receptor activity
- ·G protein-coupled receptor binding
- ·adenylate cyclase-activating G protein-coupled receptor signaling pathway
Synaptic signalling
- ·glutamatergic synapse
- ·presynapse
- ·regulation of postsynapse assembly
Excitatory neurotransmission
- ·glutamatergic synapse
Immune signalling
- ·Receptor for the lysosphingolipid sphingosine 1-phosphate (S1P) (PubMed:10617617, PubMed…
View underlying pathways (2)Hide underlying pathways
Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.
Interaction neighbourhood
Proteins with the strongest functional or physical association. Node size and line weight reflect STRING confidence; hover or select a partner to inspect one association.
Functional and physical associations from STRING v12.0. Only associations with this protein are drawn — partner-to-partner links are not part of this evidence.
Drugs targeting this protein
Whether each drug engages this protein directly or through a complex, and how many other targets are recorded for it. Direct binders with few recorded targets are listed first.
Sphingosine 1-phosphate receptor agonist
Appears in clinical studies involving multiple sclerosis, relapsing-remitting multiple sclerosis, kidney transplant
ChEMBL mechanism, action type and target identity. Open Targets clinical status and indications.
Translational evidence
Why this target matters therapeutically — disease associations, drugs in development, tractability and safety, from Open Targets.
Strongest genetic associations
Human genetic evidence — the most direct causal link between this target and a disease.
Highest-confidence therapeutic associations
Diseases where a drug acting on this target has already reached clinical development.
Show all associationsHide all associations
Open Targets ranks 1,369 associations for this target and we store the top 10 by aggregated score. The long tail is largely literature co-mention and RNA-expression evidence, not evidence that this target drives those diseases.
Known drugs · 5 total
multiple sclerosis · relapsing-remitting multiple sclerosis · kidney transplant
Crohn disease · multiple sclerosis · psoriasis
multiple sclerosis
ulcerative colitis · multiple sclerosis · systemic lupus erythematosus
primary progressive multiple sclerosis · multiple sclerosis · relapsing-remitting multiple sclerosis
Tractability
Clinical trials
Trials of drugs that target this protein — reached indirectly through those drugs, so a trial listed here studies the drug, not the protein.
ClinicalTrials.gov via the drug-target graph.
Forefront confidence
Our own weighting of the evidence behind each disease association. Human genetics and clinical evidence count for most; literature co-mention counts for little, because two entities sharing an abstract is not evidence that one drives the other.
This ranking differs from Open Targets' own: re-weighting moves genetically-evidenced diseases above more heavily co-mentioned ones. The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the underlying per-type scores are shown above so the calculation can be checked.
What's happening now
Recent activity around this target, drawn from one canonical event stream. Every item is reached through a drug that targets this protein, so each event is news about that drug rather than about the protein directly.
- New publicationGlial Sphingosine-Mediated Epigenetic Regulation Stabilizes Synaptic Function in <i>Drosophila</i> Models of Alzheimer's Disease.
- Regulatory approval
Approval: Fingolimod Accord (EMA)
- Regulatory approval
Approval: Gilenya (EMA)
Objective event titles are shown unmodified; the event kind and significance line are derived from structured fields. Forefront AttentionEvent stream aggregating Europe PMC Regulatory filings ClinicalTrials.gov.